Jiménez ZVH, Martínez LE, Gallardo ALA

Idioma: Español
Referencias bibliográficas: 201
Paginas: 113-127
Archivo PDF: 255.07 Kb.

RESUMEN

La afectación pulmonar es común en pacientes con hipertensión portal y puede manifestarse de diversas maneras. Los cambios en las resistencias pulmonares se muestran como síndrome hepatopulmonar o hipertensión portopulmonar y se han documentado con elevada frecuencia en años recientes. Esta revisión resume los hallazgos clinicopatológicos, criterios diagnósticos y últimos conceptos en la patogénesis y el tratamiento de la hipertensión portopulmonar, la cual se define como la elevación de la presión arterial pulmonar por el incremento en las resistencias vasculares pulmonares y la presión capilar en cuña normal en un paciente con hipertensión portal.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Scott VL, Dodson SF, Kang Y. The hepatopulmonary syndrome. Surg Clin North Am 1999;79(1):23-39.

2. Jones FD, Kuo PC, Johnson LB, et al. The coexistence of portopulmonary hypertension and hepatopulmonary syndrome. Anesthesiology 1999;2:626-30.

3. Tasaka S, Kanazawa M, Nakamura H, et al. An autopsied case of primary pulmonary hypertension complicated by hepatopulmonary syndrome. Nihon Kyobu Shikkan Gakkai Zasshi 1995;33:90-94.

4. DeWolf A, Scott V, Gasior T. Pulmonary hypertension and liver transplantation. Anesthesiology 1993:78:213.

5. Kaspar MD, Ramsay MA, Shuey CB, et al. Severe pulmonary hypertension and amelioration of hepatopulmonary syndrome after liver transplantation. Liver Transpl Surg 1998;4:177-9.

6. Mal H, Burgiere O, Durand F, et al. Pulmonary hypertension following hepatopulmonary syndrome in a patient with cirrhosis. J Hepatol 1999;31:360-4.

7. Martinez-Pali G, Barvera JA, Taura P, et al. Severe portopulmonary hypertension after liver transplantation in a patient with preexisting hepatopulmonary syndrome. J Hepatol 1999;31;1075-9.

8. The international primary pulmonary hypertension study. Chest 1994;105:37S-41S.

9. Krowka MJ, McGoon MD. Portopulmonary hypertension: the next step. Chest 1997;112:869-0.

10. Kuo PC, Plotkin JS, Gaine S, et al. Portopulmonary hypertension and the liver transplant candidate. Transplantation 1999;67:1087-93.

11. Mackworth-Young CG, Gharavi AE, Boey ML, et al. Portal and pulmonary hypertension in a case of systematic lupus erythematosus: possible relationship with a clotting abnormality. Eur J Rheum Inflamm 1984;7:71-4.

12. Bayraktar Y, Tanaci N, Egesel T, el al. Antiphospholipid syndrome presenting as portopulmonary hypertension. J Clin Gastroenterol 2001;32:359-61.

13. De Clerck LS, Michielsen PP, Ramael MR, et al. Portal and pulmonary vessel thrombosis associated with systemic lupus erythematosus and anticardiolipin antibodies. J Rheumatol 1991;18:1919-21.

14. Sawai T, Tutikawa K, Watanabe T, et al. A case of mixed connective tissue disease complicating pulmonary hypertension and portal hypertension. Ryumachi 1988;28:164-9.

15. Ozawa T, Nakagawa O, Hasewaga S, et al. A case of mixed connective tissue accompanied with idiopathic portal hypertension and pulmonary hypertension. Nippon Naika Gakkai Zasshi 1989;78:1799-800.

16. Chaves E. The pathology of the arterial pulmonary vasculature in Manson’s schistosomiasis. Dis Chest 1966;50:72-77.

17. Emanuel A, Prata A, Bina JC, et al. Peristent schistosomal pulmonary hypertension in a patient after reversion of a hepato-splenic form: presentation of a case. Rev Soc Bras Med Trop 1986;19:171-2.

18. Watt G, Long GW, Calubaquib C, et al. Cardiopulmonary involvement rare in severe Schistosoma japonicum infection. Tro Geogr Med 1986;38:233-9.

19. Cornet A, Barbier JP, Debesse B, et al. Sarcoidosis and portal and pulmonary hypertension: a case report. Ann Intern Med 1980;131:431-4.

20. Salazar A, Mana J, Sala J, et al. Combined portal and pulmonary hypertension and sarcoidosis. Respiration 1994;61:117-9.

21. Kuramochi S, Tashiro Y, Torikata C, et al. Systemic lupus erythematosus associated with multiple nodular hyperplasia of the liver. Acta Pathol Jpn 1982;32:547-60.

22. Ansari A, Larson PH, Bates HD. Vascular manifestations of systemic lupus erythematosus. Angiology 1986;37:423-32.

23. Pare PD, Chan-Yan C, Wass H, et al. Portal and pulmonary hypertension with microangiopathic hemolytic anemia. Am J Med 1983;74:1093-6.

24. Mandell MS, Groves BM. Pulmonary hypertension in chronic liver disease. Clin Chest Med 1996;17:17-33.

25. Mantz FA, Craig E. Portal axis thrombosis with spontaneous porto-caval shunt and resultant cor pulmonale. Arch Pathol Lab Med 1951;52:91-7.

26. A fifty six year old woman with jaundice and pulmonary hypertension. Am J Med 1969;47:287-98.

27. Levine OR, Harris RC, Blanc WA, et al. Progressive pulmonary hypertension in children with portal hypertension. J Pediatr 1973;83:964-72.

28. Lebrec D, Capron JP, Dhumeaux D, et al. Pulmonary hypertension complicating portal hypertension. Am Rev Respir Dis 1979;120:849-56.

29. Molden D, Abraham JL. Pulmonary hypertension: its association with hepatic cirrhosis and iron accumulation. Arch Pathol Lab Med 1982;106:328-31.

30. Wagenvoort CA. Medial defects of lung vessels: a new cause of pulmonary hypertension. Hum Pathol 1986;17:722-6.

31. Booth H, Visser FC, Thijs JC, et al. Pulmonary hypertension complicating portal hypertension: a case report with suggestions for a different therapeutic approach. Eur Heart J 1987;10:656-60.

32. Edwards BS, Weir EK, Edwards WD, et al. Coexistent pulmonary and portal hypertension: morphologic and clinical features. J Am Coll Cardiol 1987;10:1233-8.

33. Chan T, Palevski HI, Miller WT, et al. Pulmonary hypertension complicating portal hypertension: findings on chest radiographs. AJR Am J Roentgenol 1988;151:909-14.

34. Maev IV, Merzilikin LA, Vorobev LP, et al. Study of the right heart and external respiratory functions in patients with liver cirrhosis by doppler echocardiography. Sov Med 1991;8:11-13.

35. Hadengue A, Benhayoun MK, Lebrec D, et al. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991;100:520-8.

36. Robalino BD, Moodie DS. Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. J Am Coll Cardiol 1991;17:492-8.

37. Moscoso G, Mieli-Vergani G, Mowat AP, et al. Sudden death caused by unexpected pulmonary arterial hypertension, 10 years after surgery for extrahepatic biliary atresia. J Pediatr Gastroenterol Nutr 1991;12:388-93.

38. Rossi SO, Gilbert-Barnes E, Saari T, et al. Pulmonary hypertension with coexisting portal hypertension. Pediatr Pathol 1992;12:433-9.

39. Goenka MK, Mehta SK, Mallik AK, et al. Fatal pulmonary arterial hypertension complicating non-cirrhotic portal fibrosis. Am J Gastroenterol 1992;87:1203-05.

40. Yoshida EM, Erb SR, Pflugfelder PW, et al. Single lung vs liver transplantation for the treatment of portopulmonary hypertension: a comparison of two patients. Transplantation 1993;55:688-90.

41. Tokiwa K, Iwai N, Nakamura K, et al. Pulmonary hypertension as a fatal complication of extrahepatic portal hypertension. Eur J Pediatr Surg 1993;3:373-5.

42. Woolf D, Voigt MD, Jaskiewicz K, et al. Pulmonary hypertension associated with non cirrhotic portal hypertension in systemic lupus erythematosus. Postgrad Med J 1994;70:41-3.

43. Yoshida EM, Erb SR, Ostrow DN, et al. Pulmonary hypertension associated with primary biliary cirrhosis in the absence of portal hypertension: a case report. GUT 1994;35:280-2.

44. Koneru B, Ahmed S, Weisse AB, et al. Resolution of pulmonary hypertension of cirrhosis after liver transplantation. Transplantation 1994;58:1133-5.

45. Levy MT, Torzillo P, Bookallil M, et al. Case report: delayed resolution of severe pulmonary hypertension after isolated liver transplantation in a patient with cirrhosis. J Gastroenterol Hepatol 1996;11:734-7.

46. Kuo PC, Schroeder RA, Vagelos RH, et al. Volume mediated pulmonary responses in liver transplant candidates. Clin Transplant 1996;10:521-7.

47. Murata K, Shimizu A, Takase K, et al. Asymptomatic primary pulmonary hypertension associated with liver cirrhosis. J Gastroenterol 1997;32:102-4.

48. Rich S. Primary pulmonary hypertension: executive summary from the world symposium. WHO programme on cardiovascular diseases, 1998.

49. Cohen MD, Rubin LJ, Taylor WE, et al. Primary pulmonary hypertension: an unusual case associated with extrahepatic portal hypertension. Hepatology 1983;3:588-92.

50. Soh H, Hasegawa T, Sasaki T, et al. Pulmonary hypertension associated with postoperative biliary atresia: report of two cases. J Pediatr Surg 1999;34:1779-81.

51. Klochkov SA, Alekseevskikh lu G, Seniakovich VM. Histologic changes in the lungs and heart in children with extrahepatic blockade of the portal circulation. Arkh Patol 1996;58:54-8.

52. De BK, Pal A, Santra A, et al. Primary pulmonary hypertension in non cirrhotic portal fibrosis. Indian J Gastroenterol 1997;16:85-7.

53. Sekiguchi Y, Amano K, Takano Y, et al. Portal and pulmonary hypertension in a patient with MCTD. Ryumachi 1999;39:657-63.

54. Bernthal AC, Eybel CE, Payne JA. Primary pulmonary hypertension after porto-caval shunt. J Clin Gastroenterol 1983;5:353-6.

55. Mikhelson VA, Trifonova NA, Ismail-Zade IA, et al. Disorders of hemodynamics and their correction in children with non hepatic portal hypertension during the course of surgical treatment. Nesteziol Reanimatol 1993;(1):13-6.

56. Ismail-Zade IA, Trifonova NA, Razumovski AY, et al. Haemodynamic changes in children with portal hypertension during the postoperative period. Pediatr Anaesth 1995;5:311-7.

57. McDonnell PJ, Toye OA, Hutchins GM. Primary pulmonary hypertension and cirrhosis: are they related? Am Rev Respir Dis 1983;127:437-41.

58. Sen S, Biswas PK, Biswas J, et al. Primary pulmonary hypertension in cirrhosis liver. Indian J Gastroenterol 1999;18:158-60.

59. Yang YY, Lin HC, Lee WC, et al. Portopulmonary hypertension distinctive hemodynamic and clinical manifestations. J Gastroenterol 2001;36:181-6.

60. Taura P, García Valdecasas JC, Beltrán J, et al. Moderate primary pulmonary hypertension in patients undergoing liver transplantation. Anesth Analg 1996;83:675-80.

61. Castro M, Growka MJ, Scroeder DR, et al. Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients. Mayo Clinic Proc 1996;71:543-51.

62. Ramsay MA, Simpson BR, Nguyen AT, et al. Severe pulmonary hypertension in liver transplant candidates. Liver Transplant Surg 1997;3:494-500.

63. Donovan CL, Marcovitz PA, Punch JD, et al. Two-dimensional and dobutamine stress echocardiography in the preoperative assessment of patients with end stage liver disease prior to orthotopic liver transplantation. Transplantation 1996;61:1180-8.

64. Auletta M, Oliveiro U, Lasiulolo L, et al. Pulmonary hypertension associated with liver cirrhosis: an echocardiographic study. Angiology 2000;51:1013-20.

65. Kibria G, Smith P, Heath D, et al. Observations on the rare association between portal and pulmonary hypertension. Thorax 1980;35;945-9.

66. Hiyama E. Pulmonary vascular changes after portosystemic shunt operation in rats. Nippon Geka Gakkai Zasshi 1989;90:874-85.

67. Budhiraja R, Hassoun PM. Portopulmonary hypertension; a tale of two circulations. Chest 2003;123(2):521-48.

68. Tuder RM, Cool CD, Yeager M, et al. The pathobiology of pulmonary hypertension: endothelium. Clin Chest Med 2001;22:405-18.

69. Yeager ME, Halley GR, Golpon HA, et al. Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circ Res 2001;88:E2-E11.

70. Higenbottam TW, Laude EA. Endothelial dysfunction providing the basis for the treatment of pulmonary hypertension. Giles F. Filley lecture. Chest 1998;114:72S-9S.

71. Fishman AP. Etiology and pathogenesis of primary pulmonary hypertension: a perspective. Chest 1998;114:242S-7S.

72. Welsh CH, Hassell KL, Badesch DB, et al. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest 1996;110:710-7.

73. Gerber JG, Voelkel N, Nies AS, et al. Moderation of hypoxic vasoconstriction by infused arachidonic acid; role of PGI2. J Appl Physiol 1980;49:107-12.

74. Geraci MW, Gao B, Sheperd DC, et al. Pulmonary prostacyclin synthase overexpression in transgenic mice protect against development of hypoxic pulmonary hypertension. J Clin Invest 1999;103:1509-15.

75. Hara S, Morishita R, Tone Y, et al. Overexpression of prostacyclin synthase inhibits growth of vascular smooth muscle cells. Biochem Biophys Res Commun 1995;216:862-7.

76. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. NEJM 1992;327:70-5.

77. Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999;159:1925-32.

78. Hassoun PM, Thappa V, Landmann MJ, et al. Endothelin 1 mitogenic activity on pulmonary artery smooth muscle cells and release from hypoxic endothelial cells. Proc Soc Exp Biol Med 1992;199:165-70.

79. Stelzner TJ, O’Brien RF, Yanagiosawa M, et al. Increased lung endothelin 1 production in rats with idiopathic pulmonary hypertension. Am J Physiol 1992;262:L614-L20.

80. Yoshibayashi M, Nishioka K, Nakao K, et al. Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects: evidence for increased production of endothelin in pulmonary circulation. Circulation 1991;84:2280-5.

81. Cody RJ, Haas GJ, Binkley PF, et al. Plasma endothelin 1 correlates with extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992;85:504-9.

82. Stewart DJ, Levy RD, Cernacek P, et al. Increased plasma endothelin 1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991;114:464-9.

83. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. NEJM 1993;328:1732-9.

84. Vincent JA, Ross RD, Kassab J, et al. Relation of elevated plasma endothelin in congenital heart disease to increased pulmonary blood flow. Am J Cardiol 1993;71:1204-7.

85. Chang H, WuGJ, Wang SM, et al. Plasma endothelin-1 levels and surgically correctable pulmonary hypertension. Ann Thorac Surg 1993;55:450-8.

86. Kamath PS, Tyce GM, Miller VM, et al. Endothelin-1 modulates intrahepatic resistance in a rat model of non cirrhotic portal hypertension. Hepatology 1999;30:401-7.

87. Moore K, Wendon J, Frazer M, et al. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. NEJM 1992;327;1774-8.

88. Zhan Q, Guo J, Tang J, et al. Alternation of the level of plasma calcitonin gene related peptide and endothelin-1 in liver cirrhosis. Zhongua Nei Ke Za Zhi 1999;38:91-3.

89. Shah V, Torurner M, Haddad F, et al. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology 1999;117:1222-8

90. Cella G, Bellotto F, Tona F, et al. Plasma markers of endothelial dysfunction in pulmonary hypertension. Chest 2001;120:1226-30.

91. Nichols WC, Koller DL, Slovis B, et al. Localization of the gene for familial primary pulmonary hypertension chromosome 2q31-32. Nat Gene 1997;15:277-80.

92. Morse JH, Jones AC, Barst RJ, et al. Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32. Circulation 1997;95:2603-6.

93. Eddahibi S, Humbert M, Fadel E, et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 2001;108:1141-50.

94. Flemale A, Sabot JP, Popijn M, et al. Pulmonary hypertension associated with portal thrombosis. Eur J Respir Dis 1985;66:224-8.

95. Egermayer P, Town GI, Peacock AJ. Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension. Thorax 1999;54:161-8.

96. Lee SL, Wang WW, Lanzillo JJ, et al. Serotonin produces both hyperplasia and hypertrophy of bovine pulmonary artery smooth muscle cell culture. Am J Physiol 1994;266:L46-L52.

97. Eddahibi S, Chouaid C, Sediame S, et al. Serotonin uptake and citalopram binding in platelets from patients with chronic pulmonary hypertension. Am J Respir Crit Care Med 1999;159A:165.

98. Herve P, Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995;99:249-54.

99. Laffi G, Marra F, Gresele P, et al. Evidence for a storage pool defect in platelets from cirrhotic patients with deffective aggregation. Gastroenterology 1992;103;641-6.

100. Senior RM, Britton RC, Turino GM, et al. Pulmonary hypertension associated with cirrhosis of the liver and with portocaval shunts. Circulation 1968;37:88-96.

101. Lai KS, McFadzean AJ, Yeung R. Microembolic pulmonary hypertension in pyogenic cholangitis. BMJ 1968;30:723-5.

102. Lal S, Fletcher E. Pulmonary hypertension and portal venous system thrombosis. Br Heart J 1968;30:723-5.

103. Herve P, Lebrec D, Brenot F, et al. Pulmonary vascular disorders in portal hypertension. Eur Respir J 1998;11:1153-66.

104. Larrey D, Theodore C, Molas G, et al. Primary biliari cirrhosis and pulmonary arterial hypertension. Gastroenterol Clin Biol 1981;5:588-9.

105. Wallwork J, Williams R, Calne RY. Transplantation of liver, heart and lungs for primary biliary cirrhosis and primary pulmonary hypertension. Lancet 1987;2;182-5.

106. Mansour M, Lassabe G, Rauscher M, et al. Pulmonary arterial hypertension and primary biliary cirrhosis. Arch Mal Coreur Vaiss 1995;88:503-5.

107. Koening A, Dietle A, Chauvin M, et al. Primary pulmonary hypertension associated with primary biliary cirrhosis. Press Med 1998;27;1329.

108. Aoki A, Kenmochi H, Hagiwara E, et al. Pulmonary hypertension in a patient with primary Sjogren’s syndrome, Hashimoto disease and primary biliary cirrhosis. Nihon Rinsho Meneki Gakkai Kaishi 2000;23;462-9.

109. Carter EP, Sato K, Morio Y, et al. Inhibition of K (Ca) channels restores blunted hypoxic pulmonary vasoconstriction in rats with cirrhosis. Am J Physiol Lung Cell Mol Physiol 2000;279:L903-L10.

110. Yi ES, Kim H, Ahn H, et al. Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension: a morphometric and immunohistochemical study. Am J Respir Crit Care Med 2000;162:1577-86.

111. Cool CD, Stewart JS, Werahera P, et al. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell specific markers: evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol 1999;155:411-9.

112. Pietra GG, Edwards WD, Kay JM, et al. Histopathology of primary pulmonary hypertension; a qualitative and quantitative study of pulmonary blood vessels from 58 patients in the national heart, lung and blood institute, primary pulmonary hypertension registry. Circulation 1989;80:1198-206.

113. Mason NA, Springall DR, Burke M, et al. High expression of endothelial nitric oxide synthase in plexiform lesions of pulmonary hypertension. J Pathol 1998;185:313-8.

114. Kuo PC, Plotkin JS, Johnson LB, et al. Distinctive clinical features of portopulmonary hypertension. Chest 1997;112:980-6.

115. Prager M, Cauldwell C, Ascer N, et al. Pulmonary hypertension associated with liver disease. Anesthesiology 1992;77:375-8.

116. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension; a national prospective study. Ann Intern Med 1987;107:216-23.

117. Weissman E, Becker NH. Interstitial lung disease in primary biliary cirrhosis. Am J Med Sci 1983;285:21-7.

118. Osaka M, Aramaki T, Okumura H, et al. Primary biliary cirrhosis with fibrosing alveolitis. Gastroenterol Jpn 1988;23:457-60.

119. Strobel ES, Bonnet RB, Werner P, et al. Bronchiolitis obliterans organizing pneumonia and primary biliary cirrhosis like lung involvement in a patient with primary biliary cirrhosis. Clin Rheumatol 1998;17:246-9.

120. Bissuel F, Bizollon T, Dijoud F, et al. Pulmonary hemorrage and glomerulonephritis in primary biliary cirrhosis. Hepatology 1992;16:1357-61.

121. Plauchu M, Chapuy H, de Montgolfier R, et al. Pleural effusions in liver cirrhosis. J Med Lyon 1970;51;641-52.

122. Valeriano V, Funaro S, Lionetti R, et al. Modification of cardiac function in cirrhotic patients with and without ascites. Am J Gastroenterol 2000;95:3200-05.

123. Epstein SK, Ciubotaru RL, Zilerberg MD, et al. Analysis of impaired exercise capacity in patients with cirrhosis. Dig Dis Sci 1998;43:1701-7.

124. Campillo B, Fouet P, Bonnet JC, et al. Submaximal oxygen consumption in liver cirhosis: evidence of severe functional aerobic impairment. J Hepatol 1990;10:163-7.

125. Grose RD, Nolan J, Dillon DF, et al. Exercise induced left ventricular dysfunction in alcoholic and non alcoholic cirrhosis. J Hepatol 1995;22;326-32.

126. Cabre E, Gassull MA. Nutritional issues in cirrhosis and liver transplantation. Curr Opinion Nutr Metab Care 1999;2:373-80.

127. Roth K, Lynn J, Zhong Z, et al. Dying with end stage liver disease with cirrhosis: insights from SUPPORT; Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment. J Am Geriatr Sc 2000;48:S122-S30.

128. Agusti AG, Roca J, Rodriguez -Roisin R. Mechanisms of gas exchange impairment in patients with liver cirrhosis. Clin Chest Med 1996;17:49-66.

129. King PD, Rumbaut R, Sanchez C. Pulmonary manifestations of chronic liver disease. Dig Dis 1996;14:73-82.

130. Daoud FS, Reeves JT, Scaefer JW. Failure of hypoxic pulmonary vasoconstriction in patients with liver cirrhosis. J Clin Invest 1972;51:1076-80.

131. Krowka MJ. Hepatopulmonary syndrome vs portopulmonary hypertension; distinctions and dilemmas. Hepatology 1997;25:1282-4.

132. Kuo PC, Plotkin. Distinctive clinical features of portopulmonary hypertension. Chest 1997;112;980-6.

133. Kim WR, Krowka MJ, Plevak DJ, et al. Accuracy of doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. Liver Transpl 2000;6:453-8.

134. Torregosa M, Genesca J, Gonzalez A, et al. Role of doppler echocardiography in the assessment of portopulmonary hypertension in liver transplantation candidates. Liver transplantation 2001;71:572-4.

135. Rettke SR, Chantigian RC, Janossy TA, et al. Anesthesia approach to hepatic transplantation. Mayo Clinic Proc 1989;64:224-31.

136. Waxman AB. Pulmonary function test abnormalities in pulmonary vascular disease and chronic heart failure. Clin Chest Med 2001;22:751-8.

137. Rhodes J, Barst RJ, Garofano RP, et al. Hemodynamic correlates of exercise function in patients with primary pulmonary hypertension. J Am Coll Cardiol 1991;18:1738-44.

138. D’Alonso GE, Gianotti L, Dantzker DR. Noninvasive assessment of hemodynamic improvement during chronic vasodilator therapy in obliterative pulmonary hypertension. Am Rev Respir Dis 1986;133:380-4.

139. Kuo PC, Johnson LB, Plotkin JS, et al. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation 1997;63:604-6.

140. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of teprostinil, a prostacyclin analogue, in patients with pulmonary hypertension; a double blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-4.

141. Nagaya N, Uematsu M, Okano Y, et al. Effect of an orally active prostacyclin analogue on survival outpatients with primary pulmonary hypertension. J Am Coll Cardiol 1999;34;1188-92.

142. Hoeper MM, Schwarze M, Ehlerding S, et al. Long term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. NEJM 2000;342:1866-70.

143. Wilkens H, Guth A, Konig J, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001;104;1218-22.

144. Nagaya N, Uematsu M, Oya H, et al. Short -term oral administration of L arginine improves hemmodynamics and exercise capacity in patients with precapillary pulmonary hypertension. Am J Respir Crit Care Med 2001;163:887-91.

145. Findlay JY, Harrison BA, Plevak DL, et al. Inhaled nitric oxide reduces pulmonary artery pressures in portopulmonary hypertension. Liver Transpl Surg 1999;5:381-7.

146. Buchhorn R, Hulpke -Wette JA, et al. B-blocker therapy in an infant with pulmonary hypertension. Eur J Pediatr 1999;158:1007-8.

147. Ribas J, Angrill J, Barbera JA, et al. Isosorbide-5 mononitrate in the treatment of pulmonary hypertension associated with portal hypertension. Eur Respir J 1999;13;210-12.

148. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. NEJM 2002;346:896-903.

149. Barst RJ, Rich S, Widlitz A, et al. Clinical efficacy of sitaxsentan, an endothelin - a receptor antagonist, in patients with pulmonary arterial hypertension; open-label pilot study. Chest 2002;121:1860-8.

150. Dennis CM, McNeil KD, Dunning J, et al. Heart lung liver transplantation. J Heart Lung Transplant 1996;15:536-8.

151. Pirenne J, Verleden G, Nevens F, et al. Combined liver and lung transplantation in candidates with refractory portopulmonary hypertension. NEJM 1992;327;76-81.

152. Rich S, Kaufmann E, Levy S, et al. The effect of high doses of calcium- channel blockers on survival in primary pulmonary hypertension. NEJM 1992;327:76-81.

153. Vorobev LP, Maev IV, Andreev NG. Drug therapy of pulmonary and portal hypertension in liver cirrhosis. Klin Med 1991;69:64-7.

154. McLaughlin VV, Genthener DE, Panella MM, et al. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension; a case series. Ann Intern Med 1999;130:740-3.

155. Krowka MJ, Fratz RP, McGoon MD, et al. Improvement in pulmonary hemodynamics during intravenous epoprostenol: a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999;30:641-8.

156. Scroeder RA, Rafii AA, Plotkin JS, et al. Use of aerosolized epoprostenol in the treatment of portopulmonary hypertension. Transplantation 2000;70:548-50.

157. Bozkurt S, Ersoy E, Tekyn HE, et al. The cytoprotective effect of iloprostol against carbon tetrachloride induced necrosis in rat liver. Res Commun Mol Pathol Pharmacol 1997;95:343-6.

158. Davies DS, Fawthrop DJ, Nasseri-Sina P, et al. Paracetamol toxicity and its prevention by cytoprotection with iloprost. Toxicol Lett 1992;64-5.

159. Nasseri-Sina P, Fawthrop DJ, Wilson J, et al. Cytoprotection by iloprost against paracetamol induced toxicity in hamster isolated hepatocytes, Br J Pharmacol 1992;105:417-23.

160. Findlay JY, Plevak DJ, Krowka MJ, et al. Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension. Liver Transpl Surg 1999;5:362-5.

161. Tilton RG, Munsch CL, Sherwood SJ, et al. Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active EI (A) receptor antagonist. Pul Pharmacol Ther 2000;13:87-97.

162. Williamson DJ, Wallman LL, Jones R , et al. Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation 2000;102:411-8.

163. De Wolf AM, Scott V, Bjerke R, et al. Hemodynamic effects of inhaled nitric oxide in four patients with severe liver disease and pulmonary hypertension. Liver Transpl Surg 1997;3:594-7.

164. Ramsay MA, Schmidt A, Hein HA, et al. Nitric oxide does not reverse pulmonary hypertension associated with end stage liver disease: a preliminary report. Hepatology 1997;25:524-7.

165. Abrams D, Schulze-Neick I, Magee AG. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 2000;84:E4.

166. Schumacher YO, Zdebick A, Huonker M, et al. Sildenafil in HIV related pulmonary hypertension. AIDS 2001;15:1747-8.

167. Zhao L, Mason NA, Morell NW, et al. Sildenafil inhibit hypoxia induced pulmonary hypertension. Circulation 2001;104:424-8.

168. Langle F, Roth E, Steininger R, et al. Arginase release following liver reperfusion: evidence of haemodynamic action of arginase infusions. Transplantation 1995;59:1542-9.

169. Kobayashi H, Nonami T, Kurokawa T, et al. Role of endogenous nitric oxid in ischemia reperfusion injury in rat liver. J Surg Res 1995;59:772-9.

170. Shimamura T, Zhu Y, Zhang S, et al. Protective role of nitric oxide in ischemia and reperfusion injury of the liver. J Am Coll Surg 1999;188:43-52.

171. Shiraishi M, Hiroyasu S, Nagahama M, et al. Role of exogenous L-arginine in hepatic ischemia reperfusion injury. J Surgery Res 1997;69:429-34.

172. Nilsson B, Yoshida T, Delbreo D, et al. Pretreatment with L-arginine reduces ischemia/reperfusion injury of the liver. Transplant Proc 1997;29:3111-2.

173. Higa T, Shiraishi M, Mamadi T, et al. Limitations of exogenous L-arginine in exerting a cytoprotective effect on hepatic ischemia/reperfusion injury. Surg Today 2000;30:352-9.

174. De Wolf AM, Scott VL, Gasior T, et al. Pulmonary hypertension and liver transplantation. Anesthesiology 1993;78:213-4.

175. Scott V, De Wolf A, Kang Y, et al. Reversibility of pulmonary hypertension after liver transplantation: a case report. Transplant Proc 1993;25:1789-90.

176. Losay J, Piot D, Bougaran J, et al. Early liver transplantation is crucial in children with liver disease and pulmonary artery hypertension. J Hepatol 1998;28:337-42.

177. Schott R, Chaouat A, Launoy A, et al. Improvement of pulmonary hypertension after liver transplantation. Chest 1999;115:1748-9.

178. Mandell MS. Hepatopulmonary syndrome and portopulmonary hypertension in the model for end stage liver disease (MELD) era. Liver Traspl 2004;10:S54-S8.

179. Krowka MJ, Plevak DJ, Findlay JY, et al. Pulmonary hemodynamics and perioperative cardiopulmonary related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transplant 2000;6:442-50.

180. Plevak D, Krowka MJ, Rettke S, et al. Successful liver transplantation in patients with mild to moderate pulmonary hypertension. Transplant Proc 1993;25:1840.

181. Rfanan AL, Maurer J, Mehta AC, et al. Progressive portopulmonary hypertension after liver transplantation treated with epoprostenol. Chest 2000;118:1497-500.

182. Mandell MS, Groves BM, Duke J. Progressive plexogenic pulmonary hypertension following liver transplantation. Transplantation 1995;59:1488-90.

183. Prager MC, Cauldwell CA, Ascher NL, et al. Pulmonary hypertension associated with liver disease is not reversible after liver transplantation. Anesthesiology 1992;77:375-8.

184. Kett DH, Acosta RC, Campos MA, et al. Recurrent portopulmonary hypertension after liver transplantation; management with epoprostenol and resolution after transplantation. Liver Transplant 2001;7:645-8.

185. Plotkin JS, Kuo PC, Rublin LJ, et al. Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. Transplantation 1998;65:457-9.

186. Tan HP, Markowitz JS, Montgomery RA, et al. Liver transplantation in patients with severe portopulmonary hypertension treated with perioperative chronic intravenous epoprostenol. Liver Transplant 2001;7:745-9.

187. Kahler CM, Graziadei I, Widemann CJ, et al. Successful use of continous intravenous prostacylicn in a patient with severe portopulmonary hypertension. Wien Klin Wochenschr 2000;112:637-40.

188. Neumann UP, Kaisers U, Langrehr JM, et al. Adminsitration of prostacyclin after liver transplantation; a placebo controlled randomized trial. Clin Transpl 2000;14;70-4.

189. Kinirons B, Kuhlman L, Mori K, et al. Management of perioperative pulmonary hypertension in a patient presenting for a portosystemic shunt. Eur J Anaesthesiol 1999;16:728-32.

190. Tarquino M, Geggel RL, Strauss RS, et al. Treatment of pulmonary hypertension with inhaled nitric oxide during hepatic transplantation in an adolescent: reversibility of pulmonary hypertension after transplantation. Clin Pediatr 1998;37:505-9.

191. Cheng DC, Edelist G. Isoflurane and primary pulmonary hypertension. Anaesthesia 1988;43:22-4.

192. Cheng EY, Woehlck HJ. Pulmonary artery hypertension complicating anesthesia for liver transplantation. Anesthesiology 1992;77:389-92.

193. Janssens SP, Bloch KD, Nong Z, et al. Adenoviral mediated transfer of the human endothelial nitric oxide synthase gene reduces acute hypoxic pulmonary vasoconstriction in rats. J Clin Invest 1996;98;317-24.

194. Campbell AI, Zhao Y, Sandhu R, et al. Cell based gene transfer of vascular endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension. Circulation 2001;104:2242-8.

195. Champion HC, Bivalacqua TJ, Toyoda K, et al. In vivo gene transfer of prepro-calcitonin gene related peptide to the lung attenuetes chronic hypoxia induced pulmonary hypertension in the mouse. Circulation 2000;101;923-30.

196. Nagaya N, Yokoyama C, Kyotani S, et al. Gene transfer of human prostacyclin synthase ameliorates monocrotaline induced pulmonary hypertension in rats. Circulation 2000;102;2005-10.

197. Mandell MS, Krowka MJ. Formation of a national database on pulmonary hypertension and hepatopulmonary syndrome in chronic liver disease. Anesthesiology 1997;87:450-1.

198. Martínez PG, Balust V, Beltran J, et al. Portopulmonary hypertension and hepatopulmonary syndrome: Two differents entities affecting pulmonary vasculature in liver disease. Crit Care Med 2005;33:1.

199. Krowka MJ. Portopulmonary hypertension: diagnostic advances and caveats. Liver Traspl 2003;9(12):1336-7.

200. Hoeper MM, Krowka MJ, Strassburgh CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 2004;363:1461-8.

201. Maruyama T, Ohsaki K, Shimoda S, et al. Thromboxane dependent portopulmonary hypertension. Am J Med 2005;118:547.